GGrantIndex
← Leaderboards

Michael Kevin Riscoe

Portland Va Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$14,982,665
Attributed
$16,821,364
Total exposure
13
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,821,364 · 9
VA$0 · 4

By mechanism

R01$14,572,608 · 6
R56$1,261,254 · 2
RC1$987,502 · 1
I01$0 · 2
IK6$0 · 1
IS1$0 · 1

Top collaborators

Most similar at Portland Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Pharmaceutical Preparations”

Research focus

Pharmaceutical PreparationsParasitesDesignInfectionIn VivoMalariaPlasmodium FalciparumOralIn VitroMulti-Drug ResistanceBloodLeadExhibitsAntimalarialsResistanceMetabolicPregnant WomenChildLiverMedicineNovel TherapeuticsResistant StrainQuinolonesDrug Kinetics

Grant awards (51)

Novel Therapeutics to Target Parasite Cytochrome bc1$620,090
R01 · FY2025 · AI · contact PI
Next Generation ELQs for Treatment and Once-Monthly Protection Against Malaria$587,318
R01 · FY2025 · AI · contact PI
Exploring 2-Biaryl-ELQs for Targeting the Qo and Qi sites of P. falciparum cyt. bc1$0
I01 · FY2025 · VA · contact PI
BLR&D Research Career Scientist Renewal Application$0
IK6 · FY2025 · VA · contact PI
Next Generation ELQs for Treatment and Once-Monthly Protection Against Malaria$686,895
R56 · FY2024 · AI · contact PI
Novel Therapeutics to Target Parasite Cytochrome bc1$620,090
R01 · FY2024 · AI · contact PI
BLR&D Research Career Scientist Renewal Award Application$0
IK6 · FY2024 · VA · contact PI
Pharmachin Optimization and Testing$0
I01 · FY2024 · VA · contact PI
Novel Therapeutics to Target Parasite Cytochrome bc1$620,090
R01 · FY2023 · AI · contact PI
Pharmachin Optimization and Testing$0
I01 · FY2023 · VA · contact PI
BLR&D Research Career Scientist Renewal Award Application$0
IK6 · FY2023 · VA · contact PI
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs$805,568
R01 · FY2022 · AI · contact PI
Novel Therapeutics to Target Parasite Cytochrome bc1$644,982
R01 · FY2022 · AI · contact PI
BLR&D Research Career Scientist Renewal Award Application$0
IK6 · FY2022 · VA · contact PI
Pharmachin Optimization and Testing$0
I01 · FY2022 · VA · contact PI
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs$776,464
R01 · FY2021 · AI · contact PI
Development of a Synergistic Drug Combination for Prevention and Treatment of Malaria$572,593
R01 · FY2021 · AI · contact PI
BLR&D Research Career Scientist Renewal Award Application$0
IK6 · FY2021 · VA · contact PI
Pharmachin Optimization and Testing$0
I01 · FY2021 · VA · contact PI
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs$816,964
R01 · FY2020 · AI · contact PI
Development of a Synergistic Drug Combination for Prevention and Treatment of Malaria$572,593
R01 · FY2020 · AI · contact PI
Design and Optimization of Novel Antimalarial Drugs$0
I01 · FY2020 · VA · contact PI
BLR&D Research Career Scientist Renewal Award Application$0
IK6 · FY2020 · VA · contact PI
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs$833,189
R01 · FY2019 · AI · contact PI
Development of a Synergistic Drug Combination for Prevention and Treatment of Malaria$572,593
R01 · FY2019 · AI · contact PI
Design and Optimization of Novel Antimalarial Drugs$0
I01 · FY2019 · VA · contact PI
Development of a Synergistic Drug Combination for Prevention and Treatment of Malaria$628,081
R01 · FY2018 · AI · contact PI
Design and Optimization of Novel Antimalarial Drugs$0
I01 · FY2018 · VA · contact PI
Development of endochin-like quinolones for babesiosis therapy$688,626
R01 · FY2017 · AI
Optimizing ELQs for Treatment and Prevention of Malaria$613,423
R01 · FY2017 · AI · contact PI
Design and Optimization of Novel Antimalarial Drugs$0
I01 · FY2017 · VA · contact PI
Optimizing ELQs for Treatment and Prevention of Malaria$613,423
R01 · FY2016 · AI · contact PI
ShEEP Request for Parkin-Elmer Spectrum Series Bio-imaging Device$0
IS1 · FY2016 · VA · contact PI
Design and Optimization of Novel Antimalarial Drugs$0
I01 · FY2016 · VA · contact PI
Optimizing ELQs for Treatment and Prevention of Malaria$613,423
R01 · FY2015 · AI · contact PI
Optimizing Pharmachins for Treatment and Prevention of Drug Resistant Malaria$0
I01 · FY2015 · VA · contact PI
Optimizing ELQs for Treatment and Prevention of Malaria$653,923
R01 · FY2014 · AI · contact PI
Optimizing Pharmachins for Treatment and Prevention of Drug Resistant Malaria$0
I01 · FY2014 · VA · contact PI
Optimizing Pharmachins for Treatment and Prevention of Drug Resistant Malaria$0
I01 · FY2013 · VA · contact PI
Optimizing ELQs for Treatment and Prevention of Malaria$574,359
R56 · FY2012 · AI · contact PI
Antitoxoplasmosis Drug Design and Optimization$365,943
R01 · FY2012 · AI · contact PI
Optimizing Pharmachins for Treatment and Prevention of Drug Resistant Malaria$0
I01 · FY2012 · VA · contact PI
Antitoxoplasmosis Drug Design and Optimization$365,721
R01 · FY2011 · AI · contact PI
Development of a Chloroquine Replacement Drug$469,451
RC1 · FY2010 · AI · contact PI
Antitoxoplasmosis Drug Design and Optimization$369,155
R01 · FY2010 · AI · contact PI
Development of a Chloroquine Replacement Drug$518,051
RC1 · FY2009 · AI · contact PI
Antitoxoplasmosis Drug Design and Optimization$384,198
R01 · FY2009 · AI · contact PI
Halogenated Xanthones as Antimalarial Agents$346,658
R01 · FY2006 · AI · contact PI
Halogenated Xanthones as Antimalarial Agents$355,000
R01 · FY2005 · AI
Halogenated Xanthones as Antimalarial Agents$355,000
R01 · FY2004 · AI
Halogenated Xanthones as Antimalarial Agents$177,500
R01 · FY2003 · AI